Stock Data
$0.00 (0.00%)
Asset Type
N/A
Exchange
N/A
Currency
N/A
Country
N/A
Sector
N/A
Industry
N/A
uniQure N.V., based in Amsterdam, specializes in pioneering gene therapies for rare and severe diseases. Its notable product, HEMGENIX, targets hemophilia B and has successfully completed a crucial Phase III trial. The company is also advancing treatments for Huntington’s disease, ALS, temporal lobe epilepsy, Fabry disease, Alzheimer’s, and Parkinson’s through various stages of clinical and preclinical development. Founded in 1998, uniQure is at the forefront of genetic medicine, aiming to transform the lives of patients with groundbreaking treatments.
uniQure's gene therapy pipeline pivots into focus as the company plans a Huntington's disease BLA submission in Q3, four-year clinical data due in September, and a 2030 cash runway into place despite an EPS miss tied to foreign currency swings and warrant fair value losses.
12 Articles
Our top personal finance-related articles today. Your wallet will thank you later.
